Cannara BiotechLOVFF +5.52%83 Days Payable is 69.85 as of Feb. 2026, which is 65% below its 10-year median of 201.33. GuruFocus rates LOVFF with a GF Score™ of 83/100 and a GF Value™ of $1.15 (Fairly Valued). The stock has 4 warning signs investors should review. Among 920 Drug Manufacturers companies, Cannara Biotech ranks worse than 63.26% on this metric.
The historical rank and industry rank for Cannara Biotech's Days Payable or its related term are showing as below:
LOVFF'
s Days Payable Range Over the Past 10 Years
Min: 63.54 Med: 201.33 Max: 2634.05
Current: 66.25
During the past 8 years, Cannara Biotech's highest Days Payable was 2634.05. The lowest was 63.54. And the median was 201.33.
LOVFF's Days Payable is ranked worse than 63.26% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs LOVFF: 66.25
Cannara Biotech's Days Payable
declined
from Feb. 2025 (73.68) to Feb. 2026 (69.85).
It may suggest that Cannara Biotechaccelerated paying its suppliers.
Cannara Biotech Days Payable Related Terms
Cannara Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cannara Biotech's Days Payable for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannara Biotech (LOVFF) has a Days Payable of 69.85 as of Feb. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cannara Biotech and its competitors. This is 65% below median its historical median of 201.33. Over the past decade, Cannara Biotech's Days Payable has ranged from 63.54 to 2,634.05. According to the industry distribution chart, Cannara Biotech ranks #582 out of 920 companies in the Drug Manufacturers industry, placing it in the top 63.3%.
Is Cannara Biotech's Days Payable too high?
Cannara Biotech's current Days Payable of 69.85 is 65% below median its 10-year median of 201.33. Over the past 10 years, this metric has ranged from a low of 63.54 to a high of 2,634.05. The Drug Manufacturers industry median Days Payable is 90.84. Cannara Biotech's value of 69.85 is 23.1% below this industry median. Based on the distribution chart, Cannara Biotech ranks #582 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cannara Biotech has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #582 out of 920 companies for Days Payable. This places Cannara Biotech in the lower half of its industry. The industry median Days Payable is 90.84. Cannara Biotech's value of 69.85 is 23.1% below this benchmark. Historically, Cannara Biotech's own Days Payable has ranged from 63.54 to 2,634.05 over the past decade. While the company's 10-year median is 201.33 vs. the industry median of 90.84, Cannara Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current Days Payable of 69.85 is 23.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current Days Payable is 69.85, which is 65% below median its own 10-year median of 201.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.15, compared to a current price of $1.21 — trading 5.5% above its estimated fair value. The current Days Payable is 69.85, which is 65% below median its 10-year median of 201.33 and 23.1% below the Drug Manufacturers industry median of 90.84. Cannara Biotech's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Days Payable is 69.85 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.21 is trading 5.5% above its estimated GF Value™ of $1.15.
GuruFocus considers Cannara Biotech to be Fairly Valued.
Key valuation signals for LOVFF:
Days Payable: 69.85 (65% below median its 10-year median of 201.33)
GF Value™: $1.15 vs. price of $1.21 (5.5% above fair value)
Industry Position: 23.1% below the Drug Manufacturers median (#582 of 920)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
83GF Score
Get the complete analysis for LOVFF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
